Table 1.
Baseline Seizure | Incident Seizure | No Seizure | ||
---|---|---|---|---|
Median [IQR] or N (%)a | Median [IQR] or N (%)a | Median [IQR] or N (%)a | P Valueb | |
N | 127 (15%) | 104 (13%) | 590 (72%) | |
Cohort | .13 | |||
2010–2012 COAT | 30 (14%) | 21 (10%) | 163 (76%) | |
2013–2014 ASTRO Pilot | 16 (11%) | 22 (15%) | 111 (74%) | |
2015–2017 ASTRO-CM | 81 (18%) | 61 (13%) | 316 (69%) | |
Demographics | ||||
Age, years | 34 [29–40] | 36 [29–42] | 35 [30–40] | .92 |
Women | 55 (43%) | 46 (44%) | 233 (39%) | .53 |
Glasgow Coma Score <15 | 78 (61 %) | 37 (36%) | 209 (36%) | <.001 |
ART status | .65 | |||
ART naive | 88 (69%) | 63 (61%) | 383 (65%) | |
On ART <4 months | 11 (9%) | 11 (11%) | 59 (10%) | |
On ART >4 months | 27 (21%) | 29 (28%) | 147 (25%) | |
Unknown ART status | 1 (1%) | 1 (1%) | 1 (0%) | |
Symptom duration, days | 21 [10–30] | 14 [12–30] | 14 [10–30] | .84 |
Blood Results | ||||
Absolute CD4 cells/μL | 14 [6–35] | 17 [6–58] | 17 [7–55] | .07 |
CD4 <50 cells/μL | 102 (84%) | 73 (74%) | 397 (72%) | .02 |
Sodium, mEq/L | 128 [124–133] | 129 [126–133] | 130 [126–134] | .19 |
Glucose, mg/dL | 110 [94–119] | 104 [86–110] | 100 [85–115] | .29 |
CSF Results | ||||
White cells/μL | <5 [<5–45] | <5 [<5–45] | <5 [<5–56] | .76 |
White cells <5 cells/μL | 71 (58%) | 59 (60%) | 323 (57%) | .88 |
Protein, mg/dL | 73 [36–120] | 62 [27–124] | 60 [24–125] | .28 |
Opening pressure, cm H2O | 33 [21–47] | 27 [19–45] | 26 [17–37] | .002 |
Opening pressure >25 cm H2O | 77 (68%) | 49 (54%) | 261 (51%) | .004 |
Cryptococcus CFU/mL CSF | 125 000 [12 400–567 000] | 92 000 [6883–360 000] | 36 000 [1011–230 000] | <.001 |
Abbreviations: ART, antiretroviral therapy; CFU, colony-forming units; COAT, Cryptococcal Optimal ART Timing; CSF, cerebrospinal fluid; IQR, interquartile range.
aPercentages of each seizure group are displayed for categorical variables.
b P values from Kruskal-Wallis tests for continuous variables and χ 2 tests for categorical variables.